Current Cancer Drug Targets: Editorial

Current Cancer Drug Targets

Volumn 10, Issue 1, 2010, Pages 1-2

  Vincenzi, Bruno ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; ZOLEDRONIC ACID;

BREAST CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; CLINICAL TRIAL; DRUG TARGETING; EDITORIAL; HUMAN; MALIGNANT MESOTHELIOMA; METHODOLOGY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE SUBPOPULATION; BIOASSAY; NEOPLASM; PHASE 2 CLINICAL TRIAL; SAMPLE SIZE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; SAMPLE SIZE;

EID: 77955296457     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910790980214     Document Type: Editorial

References (10)

1. Eisenhauer, E. A. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. Ann. Oncol. 1998, 10, 1047-1052.
2. Gelmon, K. A.; Eisenhauer, E. A.; Harris, A. L.; Ratain, M. J.; Workman, P. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development? J. Natl. Cancer Inst. 1999, 91, 1281-1287.
3. Korn, E. L.; Arbuck, S. G.; Pluda, J. M.; Simon, R.; Kaplan, R. S.; Christian, M. C. Clinical trial designs for cytostatic agents: Are new approaches needed? J. Clin. Oncol. 2001, 19, 265-272.
4. Ratain, M. J. Phase II oncology trials: Let's be positive. Clin. Cancer Res. 2005, 11, 5661-5662.
5. Ratain, M. J.; Eckhardt, S. G. Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J. Clin. Oncol. 2004, 22, 4442-4445.
6. Murray, N.; Coppin, C.; Coldman, A.; Pater, J.; Rapp, E. Drug delivery analysis of the Canadian multicenter trial in non-small cell lung cancer. J. Clin. Oncol. 1994, 12, 2333-2339.
7. Dent, S.; Zee, B.; Dancey, J.; Hanauske, A.; Wanders, J.; Eisenhauer, E. Application of a new multinomial phase II stopping rule using response and early progression. J. Clin. Oncol. 2001, 19, 785-791.
8. Zee, B.; Melnychuk, D.; Dancey, J.; Eisenhauer, E. Multinomial phase II cancer trials incorporating response and early progression. J. Biopharm. Stat. 1999, 9, 351-363.
9. Kopec, J. A.; Abrahamowicz, M.; Esdaile, J. M. Randomized discontinuation trials: Utility and efficiency. J. Clin. Epidemiol. 1993, 46, 959-971.
10. Rosner, G. L.; Stadler, W.; Ratain, M. J. Randomized discontinuation design: Application to cytostatic antineoplastic agents. J. Clin. Oncol. 2002, 20, 4478-4484.